

CADTH REIMBURSEMENT REVIEW

Stakeholder Feedback on Draft Recommendation

brolocizumab (Beovu)

(Novartis Pharmaceuticals Canada Inc.)

Indication: For the treatment of diabetic macular edema.

January 6, 2023

Disclaimer: The views expressed in this submission are those of the submitting organization or individual. As such, they are independent of CADTH and do not necessarily represent or reflect the view of CADTH. No endorsement by CADTH is intended or should be inferred.

By filing with CADTH, the submitting organization or individual agrees to the full disclosure of the information. CADTH does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting stakeholder group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission.

CADTH Reimbursement Review

Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	SR0747
Name of the drug and Indication(s)	Brolucizumab (Beovu) for diabetic macular edema
Organization Providing Feedback	FWG

1. Recommendation revisions		
Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.		
Request for Reconsideration	Major revisions: A change in recommendation category or patient population is requested	<input type="checkbox"/>
	Minor revisions: A change in reimbursement conditions is requested	<input type="checkbox"/>
No Request for Reconsideration	Editorial revisions: Clarifications in recommendation text are requested	<input type="checkbox"/>
	No requested revisions	<input checked="" type="checkbox"/>

2. Change in recommendation category or conditions
Complete this section if major or minor revisions are requested
Please identify the specific text from the recommendation and provide a rationale for requesting a change in recommendation.

3. Clarity of the recommendation
Complete this section if editorial revisions are requested for the following elements
a) Recommendation rationale
Please provide details regarding the information that requires clarification.
b) Reimbursement conditions and related reasons
Please provide details regarding the information that requires clarification.

c) Implementation guidance

Please provide high-level details regarding the information that requires clarification. You can provide specific comments in the draft recommendation found in the next section. Additional implementation questions can be raised here.

Outstanding Implementation Issues

In the event of a positive draft recommendation, drug programs can request further implementation support from CADTH on topics that cannot be addressed in the reimbursement review (e.g., concerning other drugs, without sufficient evidence to support a recommendation, etc.). Note that outstanding implementation questions can also be posed to the expert committee in Feedback section 4c.

Algorithm and implementation questions

1. Please specify sequencing questions or issues that should be addressed by CADTH (oncology only)

- 1.
- 2.

2. Please specify other implementation questions or issues that should be addressed by CADTH

- 1.
- 2.

Support strategy

3. Do you have any preferences or suggestions on how CADTH should address these issues?

May include implementation advice panel, evidence review, provisional algorithm (oncology), etc.

CADTH Reimbursement Review Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	SR0747-000
Brand name (generic)	Beovu (brolucizumab)
Indication(s)	Diabetic Macular Edema (DME)
Organization	Novartis Pharmaceuticals Canada Inc.
Contact information ^a	[REDACTED]
Stakeholder agreement with the draft recommendation	
1. Does the stakeholder agree with the committee's recommendation.	Yes <input checked="" type="checkbox"/>
	No <input type="checkbox"/>
Novartis Pharmaceuticals Canada Inc. agrees that the committee's recommendation is aligned with the evidence from the clinical trials and with clinical practice.	
Expert committee consideration of the stakeholder input	
2. Does the recommendation demonstrate that the committee has considered the stakeholder input that your organization provided to CADTH?	Yes <input checked="" type="checkbox"/>
	No <input type="checkbox"/>
Overall, the recommendation demonstrates that the committee has considered the feedback pertaining to the clinical and economic data that were submitted as part of the assessment.	
Clarity of the draft recommendation	
3. Are the reasons for the recommendation clearly stated?	Yes <input checked="" type="checkbox"/>
	No <input type="checkbox"/>
The reasons for the recommendation are clearly stated.	
4. Have the implementation issues been clearly articulated and adequately addressed in the recommendation?	Yes <input checked="" type="checkbox"/>
	No <input type="checkbox"/>
The implementation issues have been clearly articulated and adequately addressed in the recommendation.	
5. If applicable, are the reimbursement conditions clearly stated and the rationale for the conditions provided in the recommendation?	Yes <input checked="" type="checkbox"/>
	No <input type="checkbox"/>
The reimbursement conditions are clearly stated and the rationale for the conditions are provided in the recommendation.	

^a CADTH may contact this person if comments require clarification.